Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01229215 · ClinicalTrials.gov registry record · Phase 2
A Study of Safety, Tolerability, and Evidence of Activity of FCFD4514S Administered Monthly or Every Other Month to Patients With Geographic Atrophy
A Phase 2 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 2
- Development phase
- 143
- Enrollment target
NCT01229215 is a Phase 2 study that has completed, run by Genentech. The registered enrollment target is 143 participants.
The verdict
NCT01229215, a Phase 2 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 143 participants
- Enrollment target
Study Summary
This is a Phase Ib/II, multicenter, randomized, single-masked, sham-injection-controlled study of safety, tolerability, and evidence of activity of FCFD4514S intravitreal injections administered monthly or every other month in patients with geographic atrophy.
Interventions
- DRUG FCFD4514S
- DRUG sham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 143 participants |
| Start Date | 2011-02 |
| Est. Completion | 2013-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01229215
The ClinicalTrials.gov registry entry for NCT01229215 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 143 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which FCFD4514S is the first listed.
NCT01229215 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01229215 about?
NCT01229215 is a clinical study titled "A Study of Safety, Tolerability, and Evidence of Activity of FCFD4514S Administered Monthly or Every Other Month to Patients With Geographic Atrophy". This is a Phase Ib/II, multicenter, randomized, single-masked, sham-injection-controlled study of safety, tolerability, and evidence of activity of FCFD4514S intravitreal injections administered monthly or every other month in patients with geographic atrophy.
What is the current status of trial NCT01229215?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 143 participants. The study started on 2011-02. Estimated completion is 2013-04.
What interventions are being tested in trial NCT01229215?
The interventions under investigation include: FCFD4514S (DRUG), sham (DRUG).
Who is sponsoring clinical trial NCT01229215?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.